{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:12:40Z","timestamp":1793041960459,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable plasma cell malignancy. In the context of the current standard of care therapies in Canada, outcomes among patients with relapsed\/refractory multiple myeloma (RRMM), particularly those with triple-class (or more) refractory disease remain poor. Immunotherapies have significantly changed the treatment landscape of MM. Since 2021, two BCMA-targeting CAR T-cell therapy products have been approved for RRMM\u2014namely Idecabtagene vicleucel (Ide-cel) (ABECMA\u00ae) and Ciltacabtagene autoleucel (Cilta-cel) (CARVYKTI\u00ae), both of which are available in the US and Europe. Although they have shown unprecedented efficacy in RRMM, their clinical and logistical limitations must be acknowledged. MM CAR T-cell therapy is likely to be approved in Canada soon. Therefore, it is timely that we review the latest evidence for commercially available CAR T-cell therapy in multiple myeloma, with a focus on its relevance and impact in the Canadian setting. There will be challenges to access and strategies must be in place to ensure equitable care for all Canadians with MM. Alongside haematologists working in the immune effector cell therapy programs, providers in the community will also play a role in the ongoing monitoring and management of long-term side effects including opportunistic infections and late neurotoxicity.<\/jats:p>","DOI":"10.3390\/curroncol31070292","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:27:20Z","timestamp":1720538840000},"page":"3949-3967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-9854","authenticated-orcid":false,"given":"Steven Chun-Min","family":"Shih","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sita","family":"Bhella","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"ref_1","unstructured":"PDQ\u00ae Adult Treatment Editorial Board (2024, April 10). PDQ Plasma Cell Neoplasms (Including Multiple Myeloma) Treatment, Available online: https:\/\/www.cancer.gov\/types\/myeloma\/patient\/myeloma-treatment-pdq."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhou, L., Yu, Q., Wei, G., Wang, L., Huang, Y., Hu, K., Hu, Y., and Huang, H. (2021). Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08280-y"},{"key":"ref_3","first-page":"m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Mailankody","year":"2020","journal-title":"BMJ"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41408-023-00946-z","article-title":"Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database","volume":"13","author":"Visram","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: What we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","first-page":"17","article-title":"Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Anderson","year":"2024","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_10","first-page":"S13","article-title":"Bispecific T-cell engagers for treatment of multiple myeloma","volume":"98","author":"Ravi","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/OP.22.00315","article-title":"Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access","volume":"18","author":"Mikhael","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Mor\u00e8, S., Corvatta, L., Manieri, V.M., Olivieri, A., and Offidani, M. (2023). Current Main Topics in Multiple Myeloma. Cancers, 15.","DOI":"10.3390\/cancers15082203"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood-2023-181762","article-title":"Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Sidana","year":"2023","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene Autoleucel, an Anti\u2013B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed\/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","volume":"41","author":"Martin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","article-title":"CARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Lin","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1200\/JCO.2023.41.16_suppl.8012","article-title":"Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-021-00507-2","article-title":"KarMMa-RW: Comparison of idecabtagene vicleucel with real-world outcomes in relapsed and refractory multiple myeloma","volume":"11","author":"Jagannath","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/bloodadvances.2021005913","article-title":"Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"6","author":"Delforge","year":"2022","journal-title":"Blood Adv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107074","DOI":"10.1016\/j.leukres.2023.107074","article-title":"Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: Longitudinal findings from the phase 2 KarMMa trial","volume":"129","author":"Delforge","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E897","DOI":"10.1016\/S2352-3026(22)00284-8","article-title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b-2, open-label study","volume":"9","author":"Martin","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.1182\/blood-2023-190583","article-title":"A Real-World Comparison of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel CAR-T Therapy: A Single Center Experience for Relapsed\/Refractory Multiple Myeloma","volume":"142","author":"Gill","year":"2023","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17474086.2022.2081147","article-title":"Idecabtagene vicleucel versus ciltacabtagene autoleucel: A Sophie\u2019s choice for patients with relapsed refractory multiple myeloma","volume":"15","author":"Davis","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2023","journal-title":"Haematologica"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.jgo.2023.101628","article-title":"Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis","volume":"15","author":"Akhtar","year":"2024","journal-title":"J. Geriatr. Oncol."},{"key":"ref_32","first-page":"350","article-title":"Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma","volume":"29","author":"Reyes","year":"2023","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1182\/blood.2023020703","article-title":"Mitigating inequity: Ethically prioritizing patients for CAR T-cell therapy","volume":"142","author":"Bell","year":"2023","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.3390\/curroncol29080412","article-title":"Access to Hematopoietic Stem Cell Transplant in Canada for Patients with Acute Myeloid Leukemia","volume":"29","author":"Morakinyo","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_37","first-page":"358","article-title":"Socioeconomic and Racial Disparity in Chimeric Antigen Receptor T Cell Therapy Access","volume":"28","author":"Ahmed","year":"2022","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/13696998.2019.1582059","article-title":"CAR T-cells: Costs, comparisons, and commentary","volume":"22","author":"Hay","year":"2019","journal-title":"J. Med. Econ."},{"key":"ref_39","first-page":"255","article-title":"Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience","volume":"29","author":"Kourelis","year":"2023","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_40","first-page":"118.e1","article-title":"Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"30","author":"Yamamoto","year":"2024","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.3390\/curroncol30040305","article-title":"CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value\u2019s Worth","volume":"30","author":"Villeneuve","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","article-title":"Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies","volume":"8","author":"Baguet","year":"2024","journal-title":"Blood Adv."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed\/Refractory Multiple Myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s11899-021-00635-3","article-title":"Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments","volume":"16","author":"Geethakumari","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.htct.2022.08.002","article-title":"CAR-T cell therapy for multiple myeloma: A practical toolkit for treatment in Brazil","volume":"45","author":"Hungria","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","volume":"389","author":"Dhakal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"CARVYKTI\u00ae Is the First and Only BCMA-Targeted Treatment Approved by the U.S (2024, May 25). FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy. [Internet]. Last Updated 6 April 2024. Available online: https:\/\/www.jnj.com\/media-center\/press-releases\/carvykti-is-the-first-and-only-bcma-targeted-treatment-approved-by-the-u-s-fda-for-patients-with-relapsed-or-refractory-multiple-myeloma-who-have-received-at-least-one-prior-line-of-therapy."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Ailawadhi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_49","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research (2024, May 25). ABECMA. BL 125736\/218 Approval Letter, 4 April 2024, Available online: https:\/\/www.fda.gov\/media\/177545\/download?attachment."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clml.2024.01.001","article-title":"SOHO State of the Art Updates Next Questions: Will CAR-TReplace ASCT in NDMM","volume":"24","author":"Jurgens","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: Phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","article-title":"CAR T therapies in multiple myeloma: Unleashing the future","volume":"31","author":"Sheykhhasan","year":"2024","journal-title":"Cancer Gene Ther."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:11:15Z","timestamp":1760109075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/7\/292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":52,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["curroncol31070292"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31070292","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]}}}